Is Novartis stock a buy right now?

We see a balanced setup. The shares sit near recent highs and most analysts rate them Hold. Consider phased entries on weakness and reassess after Q1 results on April 28. Long-term investors may stay core, while traders can keep tighter risk controls until new catalysts arrive.

What is the current Novartis price target and what does it imply?

Recent roundups show an average target of €130.28, implying roughly 8% downside from recent highs. Targets vary by broker. The cluster near current levels suggests limited short-term upside unless earnings, guidance, or pipeline news shift growth expectations meaningfully.

When is the next Novartis earnings date?

Novartis is scheduled to report Q1 2026 on April 28. Investors will focus on margins, commentary on 2026 outlook, and any pipeline or capital allocation updates. Results that beat with clean quality could support the shares. A softer print may offer better entry points.

How does SMI today influence Novartis shares?

Novartis is a heavyweight in the Swiss Market Index, so index flows and sector rotations can impact the stock. On quieter news days, large defensives often track broader moves. Strong company-specific updates, however, can decouple performance from the SMI in the short run.

Global Market Insights

Novartis Stock Today, March 03: Pullback From High as Holds Lead

ByDanny Kontos March 3, 2026March 3, 2026

Novartis stock slipped about 0.5% today, easing from last week’s 52-week high as traders locked in gains and waited for fresh data. Most analysts now rate the shares Hold, with an average Novartis price target of €130.28 that implies roughly 8% downside from recent levels. With Q1 2026 results due on April 28, risk and reward look tight near highs. For Swiss investors tracking SMI today, we break down what moved Novartis, where consensus sits, and how to think about positioning into earnings.